Top

Published in:

01-01-2017 | Literatur kommentiert

Kein Nachweis einer Ergebnisverbesserung der Salvage-Radiotherapie beim asymptomatischen biochemischen Prostatakarzinom rezidiv nach Prostatektomie durch additive Androgensuppression

Authors: Dr. Helena Garcia Schüler, Prof. Dr. Matthias Guckenberger

Published in: Strahlentherapie und Onkologie | Issue 1/2017

Auszug

Die hier vorliegende Studie untersuchte, ob die Hinzunahme einer kurzzeitigen Androgensuppression zur Salvage-Radiotherapie bei Männern mit steigendem PSA nach radikaler Prostatektomie das progressionsfreie Überleben verbessern kann [1]. …

Carrie C et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747–756CrossRefPubMed

Dearnaley DP et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4):464–473CrossRefPubMed

Kalbasi A et al (2015) Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1(7):897CrossRefPubMed

Goenka A et al (2011) Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 60(6):1142–1148CrossRefPubMed

Ost P et al (2011) High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5‑year results. Eur Urol 60(4):842–849CrossRefPubMed

Ghadjar P et al (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33(35):4158–4166CrossRefPubMed

Zapatero A et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320–327CrossRefPubMed

Shipley WU et al (2016) Report of NRG Oncology/RTOG 9601, A phase 3 trial in prostate cancer: Anti-Androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) in patients following Radical Prostatectomy (RP) with pT2-3pN0 disease and an elevated PSA. Int J Radiat Oncol Biol Phys 94(1):3CrossRef

Duchesne GM et al (2016) Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 17(6):727–737CrossRefPubMed

10.

James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177CrossRefPubMedPubMedCentral

11.

Eiber M et al (2015) Evaluation of hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668–674CrossRefPubMed

Title: Kein Nachweis einer Ergebnisverbesserung der Salvage-Radiotherapie beim asymptomatischen biochemischen Prostatakarzinom rezidiv nach Prostatektomie durch additive Androgensuppression
Authors: Dr. Helena Garcia Schüler
Prof. Dr. Matthias Guckenberger
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 1/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-1082-9

At a glance: The STEP trials

Springer Medicine

Kein Nachweis einer Ergebnisverbesserung der Salvage-Radiotherapie beim asymptomatischen biochemischen Prostatakarzinom rezidiv nach Prostatektomie durch additive Androgensuppression

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 1/2017

Patient-related quality assurance with different combinations of treatment planning systems, techniques, and machines

Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer

Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy

Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails

Dynamic contrast-enhanced MRI for automatic detection of foci ﻿of residual or recurrent disease after prostatectomy

Ist die postoperative Strahlentherapie beim lokalisierten Ewing-Sarkom mit Standardrisiko notwendig?

Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy